Last reviewed · How we verify
SYN-004
At a glance
| Generic name | SYN-004 |
|---|---|
| Sponsor | Theriva Biologics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
- A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions (PHASE1)
- A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI (PHASE2)
- A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy (PHASE1, PHASE2)
- A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy (PHASE1, PHASE2)
- Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYN-004 CI brief — competitive landscape report
- SYN-004 updates RSS · CI watch RSS
- Theriva Biologics, Inc. portfolio CI